Paciente pediátrico portador de transtorno espectro autista em um ambulatório: relato de experiência / Pediatric patient with autistic spectrum disorder in an outpatient clinic: experience report

O transtorno do espectro autista (TEA) é um grupo de distúrbios do desenvolvimento neurológico de início precoce, caracterizado por comprometimento das habilidades sociais e de comunicação, além de comportamentos estereotipados. Este trabalho teve como objetivo relatar a experiência vivenciadas durante o período das aulas práticas em um ambulatório pediátrico, pontuando a assistência de enfermagem para um paciente pediátrico com Transtorno do Espectro Autista (TEA), e os cuidados voltados para as suas enfermidades. Trata-se de um estudo descritivo do tipo relato de experiência, realizado por acadêmicas de enfermagem da Universidade da Amazônia - UNAMA, durante as aulas práticas em um ambulatório infantil em Belém – PA, concluímos que a importância do enfermeiro sobre orientar os pais, e direciona-los a consultar o filho com outros profissionais da equipe multiprofissional de saúde, e para melhorar a qualidade de vida da criança.

A list of land plants of Parque Nacional do Caparaó, Brazil, highlights the presence of sampling gaps within this protected area

Brazilian protected areas are essential for plant conservation in the Atlantic Forest domain, one of the 36 global biodiversity hotspots. A major challenge for improving conservation actions is to know the plant richness, protected by these areas. Online databases offer an accessible way to build plant species lists and to provide relevant information about biodiversity. A list of land plants of “Parque Nacional do Caparaó” (PNC) was previously built using online databases and published on the website "Catálogo de Plantas das Unidades de Conservação do Brasil." Here, we provide and discuss additional information about plant species richness, endemism and conservation in the PNC that could not be included in the List. We documented 1,791 species of land plants as occurring in PNC, of which 63 are cited as threatened (CR, EN or VU) by the Brazilian National Red List, seven as data deficient (DD) and five as priorities for conservation. Fifity-one species were possible new ocurrences for ES and MG states

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

OBJECTIVE: To evaluate whether eculizumab helps patients with anti-acetylcholine receptor-positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' status throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis) and its open-label extension. METHODS: Patients who completed the REGAIN randomized controlled trial and continued into the open-label extension were included in this tertiary endpoint analysis. Patients were assessed for the MGFA post-intervention status of improved, unchanged, worse, MM, and pharmacologic remission at defined time points during REGAIN and through week 130 of the open-label study. RESULTS: A total of 117 patients completed REGAIN and continued into the open-label study (eculizumab/eculizumab: 56; placebo/eculizumab: 61). At week 26 of REGAIN, more eculizumab-treated patients than placebo-treated patients achieved a status of improved (60.7% vs 41.7%) or MM (25.0% vs 13.3%; common OR: 2.3; 95% CI: 1.1-4.5). After 130 weeks of eculizumab treatment, 88.0% of patients achieved improved status and 57.3% of patients achieved MM status. The safety profile of eculizumab was consistent with its known profile and no new safety signals were detected. CONCLUSION: Eculizumab led to rapid and sustained achievement of MM in patients with AChR+ refractory gMG. These findings support the use of eculizumab in this previously difficult-to-treat patient population. CLINICALTRIALSGOV IDENTIFIER: REGAIN, NCT01997229; REGAIN open-label extension, NCT02301624. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, after 26 weeks of eculizumab treatment, 25.0% of adults with AChR+ refractory gMG achieved MM, compared with 13.3% who received placebo

Minimal Symptom Expression' in Patients With Acetylcholine Receptor Antibody-Positive Refractory Generalized Myasthenia Gravis Treated With Eculizumab

The efficacy and tolerability of eculizumab were assessed in REGAIN, a 26-week, phase 3, randomized, double-blind, placebo-controlled study in anti-acetylcholine receptor antibody-positive (AChR+) refractory generalized myasthenia gravis (gMG), and its open-label extension

EVALUACIÓN DEL USO DE IMPLANTES DENTALES EN PACIENTES CON DEFORMIDADES FACIALES

O uso de implantes como material restabelecedor de função e estética é comumente mencionado no cotidiano clínico, no entanto, pouco é abordado o manejo deste mesmo material em pacientes com deformidades de face, seja decorrente de perfis sindrômicos, anormalidades congênitas ou adquiridas. A atual revisão de literatura, apresenta, de forma qualitativa, os estudos reabilitadores em pacientes com diferentes aspectos de deformidades de face, realizados no período de 2014 a 2023, utilizando exclusivamente o uso de implantes como material reabilitador, seja como único tratamento proposto ou de forma multidisciplinar, trazendo em pauta a problemática enfrentada pelos pacientes e profissionais envolvidos com as respectivas menções clínicas.The use of implants as a material to restore function and aesthetics is commonly mentioned in clinical routine, however, little is addressed about the management of this same material in patients with facial deformities, whether resulting from syndromic profiles, congenital or acquired abnormalities. The current literature review presents, in a qualitative way, rehabilitative studies in patients with different aspects of facial deformities, carried out between 2014 and 2023, using exclusively the use of implants as rehabilitative material, either as the only proposed treatment or in a multidisciplinary way, bringing into focus the problem faced by patients and professionals involved with the respective clinical mentions.El uso de implantes como material para restaurar la función y la estética es comúnmente mencionados en la rutina clínica, sin embargo, poco se aborda sobre el manejo de este mismo material en pacientes con deformidades faciales, ya sean resultantes de perfiles sindrómicos, anomalías congénitas ou adquiridas. La revisión de la literatura actual presenta, de manera cualitativa, estudios de rehabilitación en pacientes con diferentes aspectos de deformidades faciales, realizado entre 2014 y 2023, utilizando exclusivamente el uso de implantes como material rehabilitador, ya sea como único tratamiento propuesto o de forma multidisciplinaria, poniendo en foco el problema enfrentado por pacientes y profesionales involucrados con las respectivas menciones clínicas

Resumos concluídos - Residência Multiprofissional

Resumos concluídos - Residência Multiprofissiona

Resumos concluídos - Saúde Coletiva

Resumos concluídos - Saúde Coletiv